Balance Sheet (Annual)

HALO / Halozyme Therapeutics, Inc. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 52,826 99,901 27,357 61,389 43,292 66,764 168,740
    Accounts Receivable Net Current 2,262 15,703 9,097 9,149 32,410 15,680 22,133
    Available For Sale Securities Current - - 44,146 74,234 65,047 138,217 300,474
    Inventory Net 567 2,671 6,170 6,406 9,489 14,623 5,146
    Prepaid Expense And Other Assets Current 8,332 12,753 8,426 10,143 21,534 21,248 13,879
    Assets Current 63,987 131,028 95,195 161,321 171,772 256,532 510,372
  Property Plant And Equipment Net 1,771 3,700 3,422 2,951 3,943 4,264 3,520
  Assets 65,759 134,728 101,793 165,977 181,789 261,515 519,945
  Prepaid Expense And Other Assets Noncurrent - - 2,676 1,205 5,574 219 5,553
  Restricted Cash And Cash Equivalents Noncurrent - - 500 500 500 500 500
Liabilities And Stockholders Equity
  Liabilities Current
    Accounts Payable Current 7,557 2,272 3,135 3,003 4,499 3,578 7,948
    Accrued Liabilities Current 5,616 7,783 14,920 13,961 26,792 28,821 39,601
    Deferred Revenue Current 4,129 8,891 7,398 7,367 9,304 4,793 6,568
    Liabilities Current 17,302 18,946 25,453 24,331 62,457 54,585 131,328
    Long Term Debt Current - 0 0 0 21,862 17,393 77,211
  Deferred Revenue Noncurrent 36,755 34,955 45,745 47,267 43,919 39,825 54,297
  Long Term Debt - 29,662 49,772 49,860 27,971 199,228 125,140
  Capital Lease Obligations Noncurrent - 1,450 0 - - - -
  Deferred Rent Credit Noncurrent 802 862 795 - - - -
  Other Liabilities Noncurrent - - 18 3,167 4,443 358 814
  Commitments And Contingencies - - - - - - -
  Stockholders Equity
    Preferred Stock Value - - 0 0 0 0 0
    Common Stock Value 104 113 115 126 128 130 143
    Additional Paid In Capital Common Stock 255,818 347,315 361,930 491,694 525,628 552,737 731,044
    Retained Earnings Accumulated Deficit -245,022 -298,574 -382,052 -450,427 -482,658 -585,342 -522,371
    Accumulated Other Comprehensive Income Loss Net Of Tax - - 17 -41 -99 -6 -450
    Stockholders Equity 10,900 48,854 -19,991 41,352 42,999 -32,481 208,366
  Liabilities And Stockholders Equity 65,759 134,728 101,793 165,977 181,789 261,515 519,945

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 40637H109